24/7 Market News Snapshot 16 October, 2025 – bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF)

October 16, 2025

DENVER, Colo., 16 October, 2025 (www.247marketnews.com) – (NASDAQ:BIAF) are discussed in this article.
BioAffinity Technologies, Inc. (BIAF), a distinguished leader in early-stage cancer diagnosis, has recently generated considerable investor interest, evidenced by a remarkable pre-market surge of 22.03%, elevating its stock price to $3.307. This surge accompanied an impressive trading volume of 10.47 million shares, reflecting robust market enthusiasm regarding the company’s advancements and potential for growth.

Central to this excitement is BioAffinity’s receipt of a notification of allowance for a crucial patent from the United States Patent and Trademark Office. This patent is integral to the company’s innovative AI-driven algorithm and flow cytometry platform, which are essential for the precise analysis of cell populations in sputum samples for lung cancer detection. The company’s flagship diagnostic test, CyPath® Lung, leverages artificial intelligence to significantly enhance diagnostic accuracy, enabling early detection of lung cancer, notably at Stage 1A.

Maria Zannes, President and CEO of BioAffinity Technologies, affirmed the transformative impact of their novel platform, emphasizing that it not only improves early detection but also reduces patient anxiety and the need for invasive procedures. The newly allowed patent, titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning,” strengthens BioAffinity’s intellectual property portfolio, now comprising a total of 18 awarded and 33 pending patents globally.

With lung cancer projected to affect over 250,000 individuals by 2025, BioAffinity’s advanced diagnostic solutions promise to meaningfully elevate patient outcomes. The CyPath® Lung test, celebrated for its sensitivity of 92% and specificity of 87%, is positioned to provide critical diagnostic insights, enhancing the capabilities of healthcare professionals. As BioAffinity Technologies continues to spearhead innovation in cancer diagnostics, it is poised to play a pivotal role in redefining patient care and outcomes in the ongoing battle against cancer.

Related news for (BIAF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.